IDEXX Laboratories, Inc. (NASDAQ:IDXX) Stake Reduced by Yousif Capital Management LLC

Yousif Capital Management LLC decreased its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 2.6% during the fourth quarter, Holdings Channel.com reports. The firm owned 13,183 shares of the company’s stock after selling 352 shares during the period. Yousif Capital Management LLC’s holdings in IDEXX Laboratories were worth $7,317,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. OFI Invest Asset Management acquired a new position in shares of IDEXX Laboratories in the 3rd quarter valued at about $25,000. Valley National Advisers Inc. increased its holdings in shares of IDEXX Laboratories by 84.6% in the 4th quarter. Valley National Advisers Inc. now owns 48 shares of the company’s stock valued at $26,000 after purchasing an additional 22 shares during the period. Geo Capital Gestora de Recursos Ltd acquired a new position in shares of IDEXX Laboratories in the 3rd quarter valued at about $28,000. Covestor Ltd increased its holdings in shares of IDEXX Laboratories by 71.8% in the 3rd quarter. Covestor Ltd now owns 67 shares of the company’s stock valued at $29,000 after purchasing an additional 28 shares during the period. Finally, Whittier Trust Co. of Nevada Inc. increased its holdings in shares of IDEXX Laboratories by 108.6% in the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 73 shares of the company’s stock valued at $32,000 after purchasing an additional 38 shares during the period. Institutional investors and hedge funds own 87.84% of the company’s stock.

Insiders Place Their Bets

In other news, SVP George Fennell sold 8,198 shares of the company’s stock in a transaction that occurred on Thursday, February 8th. The stock was sold at an average price of $573.87, for a total transaction of $4,704,586.26. Following the completion of the transaction, the senior vice president now directly owns 6,712 shares in the company, valued at $3,851,815.44. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other news, SVP George Fennell sold 8,198 shares of the company’s stock in a transaction that occurred on Thursday, February 8th. The stock was sold at an average price of $573.87, for a total transaction of $4,704,586.26. Following the completion of the transaction, the senior vice president now directly owns 6,712 shares in the company, valued at $3,851,815.44. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Jonathan Jay Mazelsky sold 12,000 shares of the company’s stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $572.61, for a total value of $6,871,320.00. Following the transaction, the chief executive officer now owns 79,247 shares of the company’s stock, valued at $45,377,624.67. The disclosure for this sale can be found here. Insiders sold 43,524 shares of company stock valued at $24,871,960 over the last 90 days. 2.11% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on IDXX shares. Barclays upped their target price on IDEXX Laboratories from $605.00 to $655.00 and gave the company an “overweight” rating in a report on Tuesday, February 6th. The Goldman Sachs Group boosted their price target on IDEXX Laboratories from $500.00 to $650.00 and gave the company a “buy” rating in a research note on Wednesday, January 17th. Piper Sandler cut IDEXX Laboratories from an “overweight” rating to a “neutral” rating and set a $525.00 price target for the company. in a research note on Tuesday, January 30th. William Blair reissued an “outperform” rating on shares of IDEXX Laboratories in a research note on Tuesday, April 9th. Finally, JPMorgan Chase & Co. boosted their price target on IDEXX Laboratories from $600.00 to $630.00 and gave the company an “overweight” rating in a research note on Tuesday, February 6th. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, IDEXX Laboratories presently has an average rating of “Moderate Buy” and a consensus price target of $591.50.

IDEXX Laboratories Stock Up 0.1 %

Shares of IDEXX Laboratories stock opened at $494.26 on Thursday. The stock has a market capitalization of $41.05 billion, a P/E ratio of 49.08, a PEG ratio of 3.80 and a beta of 1.26. The company has a quick ratio of 1.17, a current ratio of 1.57 and a debt-to-equity ratio of 0.42. The stock has a 50 day moving average price of $533.74 and a two-hundred day moving average price of $510.50. IDEXX Laboratories, Inc. has a 12-month low of $372.50 and a 12-month high of $583.39.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Monday, February 5th. The company reported $2.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.12 by $0.20. The firm had revenue of $901.60 million during the quarter, compared to analysts’ expectations of $891.88 million. IDEXX Laboratories had a return on equity of 71.66% and a net margin of 23.08%. The company’s revenue was up 8.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.05 earnings per share. Equities analysts expect that IDEXX Laboratories, Inc. will post 11.15 earnings per share for the current year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.